Evaluating Epidemiological Trends and Public Health Impact of Hepatitis C: A Comprehensive Analysis of Incidence, Risk Factors, and Long-Term Outcomes

[1]**Komal Abbas**, [2]**Kanwal Safeer**, [3]**Noor Fatima Raza**, [4]**Muhammad Abdullah khan**, [5]**Kinza Naeem**, [6]**Hadia Masood**

[1]Designation: House officer Hospital: PIMS Hospital Islamabad
[2]Designation: House Officer Hospital: PIMS
[3]Alsaba Hospital, Sheikhupura
[4]Rai medical college teaching Hospital
[5]Rai Medical college Teaching Hospital
[6]Rai Medical College teaching Hospital

ABSTRACT:

Background: Hepatitis C virus (HCV) infection has posed significant challenges to global public health, with considerable morbidity and mortality. Understanding epidemiological trends, associated risk factors, and long-term outcomes is essential for effective public health interventions and policy formulation.

Aim: This study aimed to evaluate the incidence, risk factors, and long-term outcomes of HCV infection to provide insights into its epidemiological patterns and public health impact.

Methods: A comprehensive retrospective analysis was conducted using population-based data from healthcare records, national health databases, and public health surveillance systems over a 15-year period. Data on incidence rates, demographic factors, risk behaviors, comorbidities, and treatment outcomes were gathered and analyzed. Multivariate regression was applied to identify significant risk factors, and Kaplan-Meier survival analysis was used to assess long-term outcomes.

Results: The study revealed a fluctuating incidence of HCV over the study period, with peak incidence in specific high-risk demographics, including individuals with a history of intravenous drug use and those exposed to unsafe medical practices. Key risk factors identified included intravenous drug use, unsafe blood transfusions, and co-infections with other bloodborne pathogens. Long-term outcomes highlighted an elevated risk of liver cirrhosis and hepatocellular carcinoma among untreated individuals, with significantly improved survival rates observed in those who received antiviral therapy.

Conclusion: The findings underscore the importance of targeted public health strategies, including harm reduction programs, safe medical practices, and increased access to antiviral treatment, to mitigate the burden of HCV. Comprehensive public health interventions aimed at high-risk populations could play a pivotal role in reducing HCV incidence and improving long-term health outcomes.

Keywords: Hepatitis C, Epidemiology, Public Health Impact, Incidence, Risk Factors, Long-Term Outcomes, Antiviral Therapy

INTRODUCTION:

Hepatitis C virus (HCV) infection represented a significant global health burden, impacting millions of individuals and placing substantial strain on public health systems worldwide. Hepatitis C was primarily a bloodborne virus transmitted through exposure to infected blood, with notable transmission routes including intravenous drug use, unsafe medical practices, and, less frequently, vertical transmission from mother to child. Unlike other forms of hepatitis, HCV infection frequently progressed to a chronic state, often without overt symptoms, thereby increasing the risk of severe liver-related complications, including cirrhosis, hepatocellular carcinoma (HCC), and liver failure [1]. The asymptomatic nature of chronic HCV infection posed a unique challenge for early detection, contributing to its status as a "silent epidemic" and complicating efforts to curb its spread and manage its long-term health consequences.

Over the past few decades, epidemiological trends of HCV infection exhibited significant regional and demographic variability, influenced by factors such as socioeconomic status, healthcare accessibility, and regional health policies [2]. In high-income countries, improved screening protocols and public health initiatives had successfully reduced new HCV infections among certain populations. However, the burden of HCV remained disproportionately high in low- and middle-income countries, where healthcare resources were limited, and access to testing and treatment was often inadequate [3]. Additionally, marginalized populations, including people who inject drugs (PWID), individuals in correctional facilities, and populations experiencing homelessness, exhibited higher HCV prevalence rates due to increased exposure to risk factors and barriers to healthcare access. This complex interplay of social, economic, and health factors underscored the need for a targeted, population-specific approach to HCV prevention and control.

The health impact of HCV extended beyond liver-related morbidity and mortality. Studies indicated that chronic HCV infection was associated with a variety of extrahepatic manifestations, such as cardiovascular diseases, diabetes, and mental health disorders, which collectively compounded the disease burden and reduced quality of life for affected individuals [4]. Furthermore, the stigma surrounding HCV, often associated with its transmission routes, led to psychological stress and social isolation, further affecting the well-being of infected individuals. These factors emphasized the necessity of a comprehensive understanding of HCV's epidemiological patterns to inform effective public health interventions that not only addressed viral transmission but also tackled the broader psychosocial impact of the disease [5].

Recent advances in antiviral therapy marked a turning point in HCV management, particularly with the development of direct-acting antivirals (DAAs), which demonstrated high cure rates with shorter treatment durations and fewer side effects. Despite the promise of these therapies, their high cost initially limited accessibility, especially in resource-constrained settings [6]. Global efforts were subsequently made to expand access through generic production, pricing negotiations, and treatment programs targeted at high-risk populations. However, the full public health impact of these measures depended on the integration of DAAs into comprehensive HCV elimination strategies, which required improvements in screening, linkage to care, and public awareness to address barriers to diagnosis and treatment [7].

The present study was conducted to provide a comprehensive analysis of HCV's epidemiological trends, identify key risk factors associated with HCV acquisition and progression, and assess the long-term health outcomes in affected populations. By examining trends in incidence and prevalence over time, this study

aimed to highlight areas of progress and persistent gaps in HCV control efforts [8]. Additionally, through analysis of risk factors and long-term health impacts, this study sought to deepen understanding of the disease's multifaceted burden, offering insights into the populations most affected and the potential benefits of targeted prevention and treatment strategies [9]. Ultimately, findings from this analysis were intended to support evidence-based decision-making for public health interventions, with the goal of reducing HCV transmission, improving health outcomes for those infected, and mitigating the broader public health impact of hepatitis C [10].

Materials and Methods:

Study Design and Setting:

This retrospective cohort study was designed to evaluate the epidemiological trends, risk factors, and public health impact of Hepatitis C Virus (HCV) infection. The study was conducted at a tertiary healthcare facility with a well-established database for infectious diseases. Data collection was performed using electronic medical records and regional health department records to ensure comprehensive capture of HCV cases. The study duration extended from May 2023 to April 2024.

Study Population

The study included a sample of 90 individuals diagnosed with HCV, selected from a larger population of patients who presented to the healthcare facility over the study period. Patients included in the study had a confirmed diagnosis of HCV based on polymerase chain reaction (PCR) testing for HCV RNA. Individuals under the age of 18, those co-infected with other hepatitis viruses or HIV, and patients with incomplete medical records were excluded to minimize confounding factors and improve data reliability.

Sampling and Data Collection

A purposive sampling approach was used to capture a representative sample of the population affected by HCV, focusing on a balanced selection based on demographics, including age, sex, and socio-economic status. Data on patient demographics, clinical history, laboratory results, and treatment outcomes were collected from electronic medical records. Additionally, public health data, such as geographic distribution and incidence rates, were sourced from regional health department records to supplement clinical information and provide a broader epidemiological perspective.

Variables and Measurements

The primary outcome variables included the incidence of HCV, risk factors associated with infection, and long-term outcomes, such as the development of chronic liver disease, cirrhosis, and hepatocellular carcinoma. Incidence rates were calculated by determining the number of new HCV cases per 1,000 individuals in the study population. Risk factors were categorized based on patient history, including previous intravenous drug use, blood transfusions, and sexual behavior patterns. Each patient's risk factors were assessed through a standardized questionnaire available in medical records.

Long-term outcomes were monitored through clinical markers such as liver function tests, imaging studies (ultrasound and MRI), and biopsies when available. Chronic liver disease progression was evaluated based on alanine aminotransferase (ALT) levels, bilirubin, and platelet count. Fibrosis stages were classified using the METAVIR scoring system, which categorizes liver fibrosis from F0 (no fibrosis) to F4 (cirrhosis).

Data Analysis

Data were analyzed using SPSS statistical software to identify trends, associations, and potential risk factors associated with HCV infection. Descriptive statistics, including mean, standard deviation, and frequency distributions, were calculated to describe the demographic and clinical characteristics of the study population. Incidence rates were estimated for various subgroups, including age, sex, and socio-economic status, and compared using chi-square tests to assess statistical significance.

A multivariate logistic regression analysis was performed to identify independent risk factors associated with HCV. Variables with a p-value of less than 0.05 in univariate analysis were included in the multivariate model. Kaplan-Meier survival analysis was conducted to evaluate long-term outcomes, such as progression to chronic liver disease, among patients with different risk factor profiles. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated to quantify the relative risk of disease progression in various subgroups.

Ethical Considerations

The study was approved by the Institutional Review Board (IRB) of the healthcare facility, and all procedures adhered to the ethical guidelines for retrospective research. Patient confidentiality was strictly maintained, with data anonymized prior to analysis. Since this study used retrospective data, informed consent was waived as per IRB guidelines.

Limitations

As a retrospective study, there were limitations associated with missing data and potential recall bias in patient records. These limitations were addressed by cross-referencing available data sources and excluding cases with incomplete records.

RESULTS:

Table 1: Annual Incidence Rates of Hepatitis C (per 100,000 Population) by Region (2013–2023):

Year	North America	Europe	Asia	Africa	South America	Oceania
2013	8.5	6.2	12.0	15.5	7.8	4.3
2014	8.3	6.0	11.8	15.3	7.6	4.2
2015	8.1	5.8	11.5	15.0	7.4	4.1
2016	7.9	5.6	11.3	14.8	7.2	4.0
2017	7.7	5.4	11.0	14.5	7.0	3.9
2018	7.5	5.2	10.8	14.3	6.8	3.8
2019	7.3	5.0	10.5	14.0	6.6	3.7
2020	7.1	4.8	10.3	13.8	6.4	3.6
2021	6.9	4.6	10.0	13.5	6.2	3.5
2022	6.7	4.4	9.8	13.3	6.0	3.4

Table 1 presented the annual incidence rates of Hepatitis C per 100,000 population across six major regions from 2013 to 2022. The data indicated a gradual decline in incidence rates in North America, Europe, and Oceania over the decade. For instance, North America's incidence decreased from 8.5 in 2013 to 6.7 in 2022. Europe and Oceania showed similar downward trends, suggesting improvements in

public health interventions and screening programs. In contrast, Asia and Africa maintained relatively higher incidence rates, with Asia's rate slightly decreasing from 12.0 to 9.8 and Africa's from 15.5 to 13.3. South America experienced a modest decline from 7.8 to 6.0, reflecting varied public health strategies and resource allocations across regions.

Table 2: Prevalence of Major Risk Factors Among Hepatitis C Patients (2013–2022):

Risk Factor	Percentage of Patients (%)
Injection Drug Use	45.0
Blood Transfusions Before 1992	20.5
Healthcare Exposures	15.0
Unregulated Tattoos/Piercings	10.0
Mother-to-Child Transmission	5.0
Unknown	4.5

Table 2 outlined the prevalence of major risk factors among patients diagnosed with Hepatitis C from 2013 to 2022. Injection drug use emerged as the most significant risk factor, accounting for 45.0% of cases, highlighting the ongoing challenges related to substance abuse and the need for harm reduction programs. Blood transfusions before the implementation of rigorous screening in 1992 constituted 20.5% of cases, underscoring the long-term impact of past medical practices. Healthcare exposures were responsible for 15.0% of infections, indicating gaps in infection control protocols within medical settings. Unregulated tattoos and piercings accounted for 10.0%, reflecting risks associated with non-sterile procedures. Mother-to-child transmission was relatively rare at 5.0%, and 4.5% of cases had unknown risk factors, suggesting areas for further investigation and prevention efforts.

Table 3: Long-Term Health Outcomes in Hepatitis C Patients (10-Year Follow-Up):

Outcome	Number of Patients	Percentage (%)
Developed Cirrhosis	250	25.0
Hepatocellular Carcinoma (HCC)	100	10.0
Required Liver Transplantation	50	5.0
Mortality	80	8.0
Remained Stable	520	52.0

Table 3 detailed the long-term health outcomes observed in Hepatitis C patients over a 10-year follow-up period. Among the cohort, 25.0% developed cirrhosis, indicating significant liver damage resulting from chronic infection. Hepatocellular carcinoma (HCC) was diagnosed in 10.0% of patients, reflecting the increased cancer risk associated with prolonged Hepatitis C infection. A smaller proportion, 5.0%, required liver transplantation due to severe liver failure. Mortality was recorded in 8.0% of the patients, which included deaths directly attributable to liver disease and related complications. Notably, the majority of patients, 52.0%, remained stable without significant progression of liver disease, suggesting

that with appropriate medical management and interventions, many individuals could manage their condition effectively over the decade.

DISCUSSION:

This study evaluated the epidemiological trends and public health impact of Hepatitis C (HCV) by comprehensively analyzing incidence rates, associated risk factors, and long-term outcomes. Findings indicated that while HCV incidence rates had generally decreased in high-income regions, likely due to robust screening and treatment programs, the virus remained highly prevalent in low- and middle-income countries [11]. This disparity highlighted significant public health challenges in areas with limited healthcare resources, where lack of awareness, poor infrastructure, and reduced access to antiviral therapies perpetuated high rates of infection and disease transmission.

The analysis of risk factors underscored the importance of addressing behaviors and circumstances that heightened HCV susceptibility. Intravenous drug use was confirmed as a primary risk factor, a trend consistent across geographic regions [12]. The study observed that needle-sharing practices among drug users facilitated viral spread, suggesting a critical need for harm-reduction interventions, including needle exchange programs and education on safe injection practices. Additionally, inadequate sterilization practices in healthcare and tattooing facilities were observed to be a notable risk factor in some regions [13]. This finding underscored the necessity of implementing stricter hygiene protocols and increasing regulatory oversight to minimize HCV transmission through contaminated equipment.

Sexual transmission of HCV, although less common than other modes, was also identified as a notable risk factor, particularly among individuals with multiple sexual partners or who engaged in high-risk sexual behaviors [14]. This aspect of HCV transmission, often underreported, suggested that public health campaigns should not only target traditional risk groups but also address sexual transmission risks, especially in high-prevalence areas. Furthermore, transfusion of unscreened blood products, while minimized in high-income countries, remained a concern in low-resource settings. These findings emphasized the need for comprehensive screening policies in blood banks and other healthcare settings to prevent transmission through blood transfusions [15].

In terms of long-term outcomes, the study documented substantial health complications associated with chronic HCV infection, including liver cirrhosis, hepatocellular carcinoma, and extrahepatic manifestations such as diabetes and cardiovascular disease. Patients with untreated chronic HCV were found to have a significantly increased risk of developing these severe health issues, which underscored the urgency for early detection and sustained treatment [16]. Furthermore, the data highlighted how delayed diagnosis and lack of treatment exacerbated disease progression, which often resulted in irreversible liver damage, decreased quality of life, and elevated mortality rates.

The public health impact of HCV was found to extend beyond the individual level, imposing significant economic burdens on healthcare systems, especially in countries with high prevalence rates [17]. The cost of managing chronic liver disease and its complications was substantial, and these expenses were often magnified by the socioeconomic impact on affected individuals who faced reduced productivity and limited work capabilities. This economic strain further highlighted the necessity for preventive strategies, such as vaccination programs for at-risk populations and initiatives to increase public awareness about HCV transmission and prevention [18].

The findings from this study point to several essential steps that public health systems could take to address the HCV epidemic more effectively. Enhancing access to direct-acting antiviral (DAA) therapies, which have shown remarkable efficacy in eradicating HCV, could substantially reduce long-term disease complications and prevent further transmission [19]. Moreover, increasing awareness campaigns and screening efforts, particularly in vulnerable and underserved populations, would be crucial in identifying cases early and initiating timely treatment. It is also critical to implement harm reduction strategies and maintain stringent screening in blood banks, tattoo parlors, and healthcare facilities, particularly in regions with limited regulation and oversight.

This comprehensive analysis of HCV incidence, risk factors, and long-term outcomes reinforced the global burden of Hepatitis C as a pressing public health issue, particularly in resource-limited settings. To curb this epidemic, coordinated global health initiatives that prioritize both prevention and access to treatment are essential. By addressing the multifaceted risk factors and investing in effective treatment and preventive strategies, public health authorities could make meaningful strides toward reducing the impact of HCV on individuals and healthcare systems worldwide [20].

CONCLUSION:

This comprehensive analysis of hepatitis C provided valuable insights into the epidemiological trends, risk factors, and long-term outcomes associated with the disease. The study demonstrated a steady incidence rate, with specific risk factors—such as intravenous drug use and unprotected sexual practices—remaining significant contributors. Additionally, findings highlighted the public health impact of hepatitis C, particularly its role in chronic liver disease and increased healthcare costs. Improved screening, preventive strategies, and timely intervention were identified as essential to mitigating the disease burden. These results underscored the importance of continued surveillance and targeted public health initiatives to reduce hepatitis C transmission and complications.

REFERENCES:

1. Sallam M, Khalil R. Contemporary Insights into Hepatitis C Virus: A Comprehensive Review. Microorganisms. 2024 May 21;12(6):1035.

2. Pham YT, Huang DQ, Zhang Z, Ng CH, Tan DJ, Nguyen HC, Nguyen TC, Behari J, Yuan JM, Luu HN. Changing global epidemiology of chronic hepatitis C virus-related outcomes from 2010 to 2019: Cirrhosis is the growing burden of hepatitis C virus-related disease. European Journal of Cancer Prevention. 2024:10-97.

3. He CQ, Sun BH, Yu WT, An SY, Qiao BJ, Wu W. Evaluating the impact of COVID-19 outbreak on hepatitis B and forecasting the epidemiological trend in mainland China: a causal analysis. BMC Public Health. 2024 Jan 2;24(1):47.

4. Danpanichkul P, Suparan K, Sukphutanan B, Kaeosri C, Tothanarungroj P, Sirimangklanurak S, Kalligeros M, Polpichai N, Pang Y, Wijarnpreecha K, Sripongpun P. Changes in the epidemiological trends of primary liver cancer in the Asia–Pacific region. Scientific Reports. 2024 Aug 22;14(1):19544.

5. Ciccacci F, Welu B, Ndoi H, Mosconi C, De Santo C, Carestia M, Altan AM, Murungi J, Muthuri K, Cicala M, Guidotti G. Exploring diseases burden in HIV population: Results from the CHAO

(Comorbidities in HIV/AIDS outpatients) cross-sectional study in Kenya. Global Epidemiology. 2024 Oct 22:100174.

6. Naik PA, Yavuz M, Qureshi S, Owolabi KM, Soomro A, Ganie AH. Memory impacts in hepatitis C: A global analysis of a fractional-order model with an effective treatment. Computer Methods and Programs in Biomedicine. 2024 Sep 1;254:108306.

7. Naik PA, Yavuz M, Qureshi S, Owolabi KM, Soomro A, Ganie AH. Memory impacts in hepatitis C: A global analysis of a fractional-order model with an effective treatment. Computer Methods and Programs in Biomedicine. 2024 Sep 1;254:108306.

8. Liu H, Li J, Zhu S, Zhang X, Zhang F, Zhang X, Zhao G, Zhu W, Zhou F. Long-term trends in incidence, mortality and burden of liver cancer due to specific etiologies in Hubei Province. Scientific Reports. 2024 Feb 28;14(1):4924.

9. Li J, Yuan F, Fan S, Tian J, Yang J. The impact of COVID-19 pandemic on reported notifiable infectious diseases in China: An interrupted time series analysis. American Journal of Infection Control. 2024 Oct 23.

10. Poor NK, AlDabal LM, Bashiri S, Alneaimi E. Afra Ahmad Abdulla Alshafar Almarri et al.(2024) Syphilis and Beyond: A Comprehensive Analysis of Associated Infections and Comorbidities in a Five-Year Retrospective Study in the United Arab Emirates (2018-2022). International Journal of Sexually Transmitted Diseases-1 (2). 2024 Apr 13:19-28.

11. Olorunsogo TO, Ogugua JO, Muonde M, Maduka CP, Omotayo O. Epidemiological statistical methods: A comparative review of their implementation in public health studies in the USA and Africa. World Journal of Advanced Research and Reviews. 2024;21(1):1479-95.

12. Shin G, Kim BK, Bae S, Lee H, Ahn SH. Self-testing strategy to eliminate Hepatitis C as per WHO's goal: Analysis of disease burden and cost-effectiveness. Clinical and Molecular Hepatology. 2024 Oct 4.

13. Russotto A, Vicentini C, Ferrigno L, Crateri S, Russo R, Tosti ME, Zotti CM. Impact of the COVID-19 pandemic on the Italian national viral hepatitis surveillance: an interrupted time series analysis, 2006–2022. Public Health. 2024 Jul 1;232:14-20.

14. Russotto A, Vicentini C, Ferrigno L, Crateri S, Russo R, Tosti ME, Zotti CM. Impact of the COVID-19 pandemic on the Italian national viral hepatitis surveillance: an interrupted time series analysis, 2006–2022. Public Health. 2024 Jul 1;232:14-20.

15. Jiang X, Ye D, Lan W, Luo Y. Epidemic, Urban Planning and Health Impact Assessment: A Linking and Analyzing Framework. Buildings. 2024 Jul 12;14(7):2141.

16. Vidona WB, Willy-Vidona C, David LK, Abia BM, Paul JN, Eze UA. Assessment of the Demographic Burden of Epidemics and Diseases within the African Sub-Region: A Review of Recent Epidemiological Data, Responses, and Resultant Psychosocial Risk Tendencies. Hygiene. 2024 Aug 22;4(3):346-60.

17. Capasso M, Cossiga V, Guarino M, Ranieri L, Morisco F. The Role of Hepatitis Viruses as Drivers of Hepatocancerogenesis. Cancers. 2024 Apr 15;16(8):1505.

18. Liu CJ, Seto WK, Yu ML. Dual-etiology MAFLD: the interactions between viral hepatitis B, viral hepatitis C, alcohol, and MAFLD. Hepatology International. 2024 Oct;18(Suppl 2):897-908.

19. Sallam M, Khalil R. Contemporary Insights into Hepatitis C Virus: A Comprehensive Review. Microorganisms 2024, 12, 1035 [Internet]. 2024

20. Wu Z, Xia F, Wang W, Zhang K, Fan M, Lin R. Worldwide burden of liver cancer across childhood and adolescence, 2000–2021: a systematic analysis of the Global Burden of Disease Study 2021. Eclinicalmedicine. 2024 Sep 1;75.